Industry news that matters to you.  Learn more

Archives for December 2016

Immunovia Announces the Start of PANFAM-1, the Largest Ever Prospective Multi-center Clinical Study for Early Detection of Pancreatic Cancer

Immunovia AB today announced the start of PANFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. The first site now collecting blood samples is the Spanish research center Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe offering FPC screening programs.

Menarini-Silicon Biosystems to Acquire CELLSEARCH CTC System

Menarini-Silicon Biosystems today announced they have signed an agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) system from Janssen Diagnostics, LLC. CELLSEARCH® is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only FDA-cleared CTC test, and has also been approved by China’s FDA for use in monitoring breast cancer patients. Financial details were not disclosed.